The short answer.
Side effects depend on the hormone and dose. The most common possibilities include water retention, breast tenderness, mood shifts, acne, breakthrough bleeding (in women on estrogen-progesterone protocols), hematocrit elevation and estradiol elevation (in men on testosterone), and injection-site irritation. Most side effects are dose-responsive and resolve with route or dose adjustment at the 8-12 week follow-up. Serious adverse events (thromboembolism, cardiovascular events) are rare and are what the structured monitoring schedule is built to detect early.
The clinical detail.
Honest disclosure of side effects is part of good hormone practice. The list below covers what we screen for at every visit and what to call us about between visits. Most patients on properly calibrated BHRT do not experience these side effects in a clinically meaningful way; when they do, the first move is almost always dose or route adjustment, not discontinuation.
Side effects related to estrogen.
- Breast tenderness or fullness. Common in the first 2-4 weeks of estrogen initiation. Usually fades as receptor sensitivity stabilizes. Persistent or worsening tenderness warrants dose reassessment and clinical exam.
- Water retention and mild bloating. Usually transient. Dose reduction or change of route (transdermal vs oral) can resolve.
- Breakthrough bleeding or spotting. Common in the first 3-6 months of estrogen-progesterone therapy in women with intact uterus. If it persists beyond 6 months or starts after a previously stable period, ultrasound or biopsy may be indicated to rule out endometrial pathology.
- Headaches. Some patients experience hormonally driven headaches that shift with estrogen dosing. Pattern (cyclic vs constant) helps guide adjustment.
- Mood changes. Mood elevation, anxiety, or low mood can all occur. Cyclic mood symptoms often track with hormone fluctuations.
Side effects related to progesterone.
- Sedation. Oral micronized progesterone is sedating because it metabolizes to allopregnanolone. This is desirable when dosed at bedtime; problematic if dosed in the morning.
- Mood lability. A subset of women are sensitive to progesterone and experience low mood, irritability, or anxiety. Adjusting dose, switching to transdermal route, or changing dosing schedule helps in most cases.
- Mild dizziness. Usually first dose, usually transient.
- Constipation or GI changes. Less common; dose-related.
Side effects related to testosterone (women).
- Acne or oily skin. Dose-related. Reducing dose or changing route generally resolves.
- Facial hair changes. Possible at supraphysiologic dosing; uncommon at properly calibrated physiologic doses.
- Voice changes or hair loss. Rare at physiologic dosing; require dose reduction if they appear.
- Mood elevation, irritability, libido increase. Mostly desired; rarely problematic at correct dose.
Side effects related to testosterone (men).
- Hematocrit elevation (erythrocytosis). Testosterone stimulates erythropoiesis. Hematocrit above 54% increases cardiovascular risk and requires intervention — dose reduction, dosing-frequency change (weekly to twice-weekly), therapeutic phlebotomy, or pause. We check hematocrit at every lab draw on TRT.
- Estradiol elevation. A subset of men aromatize testosterone to estradiol at a rate that produces water retention, gynecomastia risk, decreased libido, or mood symptoms. Anastrozole at low dose can be added; sometimes dose reduction or twice-weekly dosing solves it without an aromatase inhibitor.
- Acne or oily skin. Common in early dose adjustment; usually fades.
- Testicular size reduction. Exogenous testosterone suppresses LH and reduces testicular testosterone production; visible reduction over months. Adding hCG to the regimen preserves testicular function.
- Worsened sleep apnea. Untreated obstructive sleep apnea can worsen on TRT. We screen and treat before initiating in patients with snoring/apnea history.
- Mood elevation. Mostly desired. Occasional irritability or aggression on supraphysiologic dosing — not on properly calibrated physiologic dosing.
Route-specific side effects.
- Injection-site reactions: redness, soreness, occasional sterile abscess. Subcutaneous administration often avoids the deeper IM site discomfort.
- Skin reactions to creams or patches: contact irritation, especially at patch sites. Rotating sites and selecting different adhesive formulations helps.
- Pellet site discomfort or extrusion: uncommon; managed by removing the affected pellet.
Rare but serious side effects.
Venous thromboembolism, stroke, cardiovascular events. These are rare on well-monitored bioidentical regimens with appropriate route selection (transdermal estrogen for thrombotic-risk patients) and risk-factor screening. The monitoring schedule is built to detect early signals (rising hematocrit, rising lipids, blood pressure elevation, new clotting symptoms) before they become clinical events.
What to call us about.
Any new chest pain, severe headache, calf pain or swelling, sudden vision change, neurologic symptoms, breast lump, post-menopausal bleeding after a stable period, or severe mood change — call. Most calls turn out to be benign explanations, but the call is the right move. Quiet escalation is worse than a false alarm.
Where this fits in our methodology.
The CLARITY methodology builds side-effect screening into every visit. Symptom rubrics, focused physical exam touchpoints, and the structured lab schedule all serve as detection mechanisms. The discipline of structured surveillance is what allows BHRT to be safe at scale. See the methodology in full.
For the BHRT service, see the BHRT service page. For safety detail, see the FAQ on BHRT safety.